{
  "abstract": "Background: Body-composition changes during routine obesity pharmacotherapy require cautious interpretation. Methods: This retrospective observational cohort included 59 adults with paired InBody 770 assessments: 53 receiving tirzepatide and 6 receiving semaglutide. Paired changes and relative device-estimated muscle mass loss were analyzed in all 59; component-share analyses were restricted to the 51 achieving ≥5% weight loss. Analyses used rank-based methods and exploratory robust regression. Results: Recorded treatment duration was a median of 7.0 months, and median observed weight loss was 12.11%. Median fat mass and device-estimated muscle mass losses were 9.9 and 2.3 kg, respectively. Among the 51 participants achieving ≥5% weight loss, median fat, device-estimated muscle, and residual shares were 73.95%, 14.91%, and 10.85%. Each additional five percentage points of weight loss was associated with 2.47 percentage points greater relative device-estimated muscle mass loss (95% CI, 1.89 to 3.05). The corresponding fully adjusted association with muscle share was −0.52 percentage points (95% CI, −1.66 to 0.62); this does not establish stability or equivalence. Final drug-specific dose intensity was not statistically associated with either outcome in the adjusted models. Conclusions: Weight loss observed in this selected, predominantly tirzepatide-treated cohort was mainly accounted for by estimated fat mass reduction. Larger observed weight-loss responses accompanied greater device-estimated muscle mass reductions. Muscle-share estimates were uncertain and model-dependent. The study cannot establish causal medication effects or functional consequences.",
  "abstract_shown": true,
  "affiliations": [
    "Doctoral School of Medicine, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania",
    "Centre for Molecular Research in Nephrology and Vascular Disease, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania",
    "Second Department of Internal Medicine, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania",
    "First Department of Internal Medicine, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania",
    "Multidisciplinary Research Center for Malignant Hematological Diseases (CCMHM), “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Cristina Tomescu"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Alin Albai"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Vlad Florian Avram"
    },
    {
      "affs": [
        3,
        4
      ],
      "name": "Sandra Timar"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Anamaria Cipu"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Bogdan Timar",
      "orcid": "0000-0002-0993-6206"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4b89p4eddygc1.bib",
  "cited_by": 0,
  "doi": "10.3390/jcm15208008",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13706178/?tool=EBI",
  "id": "4b89p4eddygc1",
  "issns": [
    "2077-0383"
  ],
  "landing_url": "https://www.mdpi.com/2077-0383/15/20/8008",
  "language": "eng",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2736|Pharmacology and Obesity Treatment"
    ]
  ],
  "openalex": "W7222268289",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13706178/pdf/?tool=EBI",
  "pmcid": "PMC13706178",
  "pmid": null,
  "published": "2026-10-01",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/4b89p4eddygc1.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:00Z",
      "native_id": "10.3390/jcm15208008",
      "source": "crossref",
      "url": "https://www.mdpi.com/2077-0383/15/20/8008"
    },
    {
      "first_seen": "2026-10-30T12:21:47Z",
      "native_id": "PMC:PMC13706178",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13706178"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2736|Pharmacology and Obesity Treatment",
      "subfield": "pharmacology-toxicology"
    }
  ],
  "title": "Weight-Loss Magnitude, Fat Mass, and Device-Estimated Muscle Mass Loss During Obesity Pharmacotherapy",
  "title_text": "Weight-Loss Magnitude, Fat Mass, and Device-Estimated Muscle Mass Loss During Obesity Pharmacotherapy",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:21:47Z",
  "url": "https://research.draconitic.com/paper/4b89p4eddygc1",
  "venue": "Journal of Clinical Medicine",
  "versions": []
}